PTPRC and neoplasm: We managed to group mice that underwent the same regimen of anti-PD1 therapy into either MPR or Non according to tumor size, and CD45+ TILs or CD8+ TILs were sorted for CYTOF or bulk RNA-seq analysis, respectively (Figures 4A, E).